Sai Life Sciences is a full-service CDMO driven by a vision to propel the launch of 25 new medicines by 2025. It works with innovator pharma and biotech companies across USA, EU & Japan, accelerating the discovery, development and manufacture of complex small molecules. Over the past two decades, Sai Life Sciences has consistently delivered on a diverse set of NCE development programs for its customers with a track record of bringing value based on quality, pricing and responsiveness. Today, the company works with 7 of the top 10 big pharma companies, as well as several small and mid-sized pharma & biotech companies, with returning customers constituting 80% of its business.
Backed by committed long-term investors, TPG Capital and HBM Healthcare Investments, Sai Life Sciences is making significant investments with a view to better serve its customers in the USA and Europe. The company recently set up its lead Discovery lab in Cambridge, USA and is in the process of setting up an R&D facility in Manchester, UK.